Abstract
Despite extensive investigation, the pathophysiology of human inflammatory bowel disease (IBD) remains incompletely understood. We examined the existence of oxidative and nitrosative stress and also alterations in epidermal growth factor (EGF) secretion in saliva of IBD patients. Saliva samples were obtained from 30 nonsmoking IBD patients including 16 Crohn’s disease (CD) patients and 16 ulcerative colitis (UC) patients and 16 age- and sex-matched controls. Samples were analyzed for thiobarbituric reactive substances (TBARS) as a marker of lipid peroxidation, ferric reducing ability (antioxidant power), and EGF and nitric oxide (NO) levels. Saliva TBARS levels increased significantly (P &< 0.01) in CD patients but not in UC patients. Analysis of antioxidant power revealed that saliva of CD patients has lower antioxidant power (P &< 0.01) than saliva of the healthy control population. The concentration of EGF was found to be increased (P &< 0.01) in saliva of CD patients in comparison to that of healthy subjects. NO levels increased in saliva of both CD and UC patients in comparison to that of healthy subjects. It is concluded that excessive NO production is present in saliva of both CD and UC patients but only saliva of CD patients is oxidatively stressed. EGF secretion is normal in UC patients, although CD patients show a significant increase in salivary EGF levels.
Similar content being viewed by others
References
Cross RK, Wilson KT: Nitric oxide in inflammatory bowel disease. Inflamm Bowel Dis 9(3):179–189, 2003
Singer II, Kawka DW, Scott S, Weidner JR, Mumford RA, Riehl TE, Stenson WF: Expression of inducible nitric oxide synthase and nitrotyrosine in colonic epithelium in inflammatory bowel disease. Gastroenterology 111:871–885, 1996
Kimura H, Hokari R, Miura S, Shigematsu T, Hirokawa M, Akiba Y, Kurose I, Higuchi H, Fujimori H, Tsuzuki Y, Serizawa H, Ishii H: Increased expression of an inducible isoform of nitric oxide synthase and the formation of peroxynitrite in colonic mucosa of patients with active ulcerative colitis. Gut 42:180–187, 1998
Playford RJ: Peptides and gastrointestinal mucosal integrity. Gut 37:595–597, 1995
Sinha A, Nightingale J, West KP, Berlanga-Acosta J, Playford RJ: Epidermal growth factor enemas with oral mesalamine for mild-to-moderate left-sided ulcerative colitis or proctitis. N Engl J Med 349(4):350–357, 2003
Miettinen PJ, Berger JE, Meneses J, Phung Y, Pedersen RA, Werb Z, Derynck R: Epithelial immaturity and multiorgan failure in mice lacking epidermal growth factor receptor. Nature 376:337–341, 1995
Boughton-Smith NK, Evans SM, Hawkey CJ, Cole AT, Balsitis M, Whittle BJ, Moncada S: Nitric oxide synthase activity in ulcerative colitis and Crohn’s disease. Lancet 342:338–340, 1993
Rachmilewitz D, Stamler JS, Bachwich D, Karmeli F, Ackerman Z, Podolsky DK: Enhanced colonic nitric oxide generation and nitric oxide synthase activity in ulcerative colitis and Crohn’s disease. Gut 36:718–723, 1995
Leonard N, Bishop AE, Polak JM, Talbot IC: Expression of nitric oxide synthase in inflammatory bowel disease is not affected by corticosteroid treatment. J Clin Pathol 51:750–753, 1998
Guihot G, Guimbaud R, Bertrand V, Narcy-Lambare B, Couturier D, Duee PH, Chaussade S, Blachier F: Inducible nitric oxide synthase activity in colon biopsies from inflammatory areas: Correlation with inflammation intensity in patients with ulcerative colitis but not with Crohn’s disease. Amino Acids 18:229–237, 2000
Kimura H, Miura S, Shigematsu T, Ohkubo N, Tsuzuki Y, Kurose I, Higuchi H, Akiba Y, Hokari R, Hirokawa M, Serizawa H, Ishii H: Increased nitric oxide production and inducible nitric oxide synthase activity in colonic mucosa of patients with active ulcerative colitis and Crohn’s disease. Dig Dis Sci 42:1047–1054, 1997
Middleton SJ, Shorthouse M, Hunter JO: Increased nitric oxide synthesis in ulcerative colitis. Lancet 341:465–646, 1993
Vento P, Kiviluoto T, Jarvinen HJ, Karkkainen P, Kivilaakso E, Soinila S: Expression of inducible and endothelial nitric oxide synthases in pouchitis. Inflamm Bowel Dis 7:120–127, 2001
Lundberg JO, Hellstrom PM, Lundberg JM, Alving K: Greatly increased luminal nitric oxide in ulcerative colitis. Lancet 344:1673–1674, 1994
Ljung T, Herulf M, Beijer E, Jacobsson H, Lundberg J, Finkel Y, Hellstrom PM: Rectal nitric oxide assessment in children with Crohn disease and ulcerative colitis: Indicator of ileocaecal and colorectal affection. Scand J Gastroenterol 36:1073–1076, 2001
Ljung T, Beijer E, Herulf M, Weitzberg E, Lundberg JO, Finkel Y, Hellstrom PM: Increased rectal nitric oxide in children with active inflammatory bowel disease. J Pediatr Gastroenterol Nutr 34:302–306, 2002
Perner A, Nordgaard I, Matzen P, Rask-Madsen J: Colonic production of nitric oxide gas in ulcerative colitis, collagenous colitis and uninflamed bowel. Scand J Gastroenterol 37:183–818, 2002
Iwashita E: Greatly increased mucosal nitric oxide in ulcerative colitis determined in situ by a novel nitric oxide-selective microelectrode. J Gastroenterol Hepatol 13:391–539, 1998
Goggins MG, Shah SA, Goh J, Cherukuri A, Weir DG, Kelleher D, Mahmud N: Increased urinary nitrite, a marker of nitric oxide, in active inflammatory bowel disease. Mediat Inflamm 10:69–73, 2001
Rees DC, Satsangi J, Cornelissen PL, Travis SP, White J, Jewell DP: Are serum concentrations of nitric oxide metabolites useful for predicting the clinical outcome of severe ulcerative colitis? Eur J Gastroenterol Hepatol 7:227–230, 1995
Dijkstra G, Zandvoort AJ, Kobold AC, de Jager-Krikken A, Heeringa P, van Goor H, van Dullemen HM, Tervaert JW, van de Loosdrecht A, Moshage H, Jansen PL: Increased expression of inducible nitric oxide synthase in circulating monocytes from patients with active inflammatory bowel disease. Scand J Gastroenterol 37:546–554, 2002
Koek GH, Verleden GM, Evenepoel P, Rutgeerts P: Activity related increase of exhaled nitric oxide in Crohn’s disease and ulcerative colitis: A manifestation of systemic involvement? Respir Med 96:530–535, 2002
Wendland BE, Aghdassi E, Tam C, Carrier J, Steinhart AH, Wolman SL, Baron D, Allard JP: Lipid peroxidation and plasma antioxidant micronutrients in Crohn disease. Am J Clin Nutr 74(2):259–264, 2001
D’Odorico A. Bortolan S, Cardin R: Reduced plasma antioxidantconcentrations and increased oxidative DNA damage in inflammatory Bowel Disease. Scand J Gastroenterol 36:1289–1294, 2001
Miralles-Barrachina O, Savoye G, Belmonte-Zalar L, Hochain P, Ducrotte P, Hecketsweiler B, Lerebours E, Dechelotte P: Low levels of glutathione in endoscopic biopsies of patients with Crohn’s colitis: The role of malnutrition. Clin Nutr 18:313–317, 1999
Ardite E, Sans M, Panes J, Romero FJ, Pique JM, Fernandez-Checa JC: Replenishment of glutathione levels improves mucosal function in experimental acute colitis. Lab Invest 8:735–744, 2000
Sido B, Hack V, Hochlehnert A, Lipps H, Herfarth C, Droge W: Impairment of intestinal glutathione synthesis in patients with inflammatory bowel disease. Gut 42:485–492, 1998
Holmes EW, Young SL, Eiznhamer D, Keshavarzian A: Glutathione content of colonic mucosa: Evidence for oxidative damage in active ulcerative colitis. Dig Dis Sci 43:1088–1095, 1998
Sturniolo GC, Mestriner C, Lecis PE, D’Odorico A, Venturi C, Irato P, Cecchetto A, Tropea A, Longo G, D’Inca R: Altered plasma and mucosal concentrations of trace elements and antioxidants in active ulcerative colitis. Scand J Gastroenterol 33:644–649, 1998
Geerling BJ, Badart-Smook A, van Deursen C, van Houwelingen AC, Russel MG, Stockbrugger RW, Brummer RJ: Nutritional supplementation with N-3 fatty acids and antioxidants in patients with Crohn’s disease in remission: Effects on antioxidant status and fatty acid profile. Inflamm Bowel Dis 6:77–84, 2000
Buffington GD, Doe WF: Altered ascorbic acid status in the mucosa from inflammatory bowel disease patients. Free Radic Res 22:131–143, 1995
D’Odorico A, Pozzato F, Minotto M, et al.: Plasma carotenoids and other antioxidant levels in Crohn’s disease. Gastroenterology 110:A897, 1996
Geerling BJ, Badart-Smook A, Stockbrugger RW, Brummer RJ: Comprehensive nutritional status in patients with long-standing Crohn disease currently in remission. Am J Clin Nutr 67:919–926, 1998
Sedghi S, Keshavarzian A, Klamut M, Einznhamer D, Zarling EJ: Elevated breath ethane levels in active ulcerative colitis: evidence for excessive lipid peroxidation. Am J Gastroenterol 89:2217–2221, 1994
Pelli MA, Trovalerelli G, Capodicasa E, De Medio GE, Bassotti G: Breath alkanes determination in ulcerative colitis and Crohn’s disease. Dis Colon Rectum 42:71–76, 1999
Grisham MB, Granger DN: Neutrophil-mediated mucosal injury. Role of reactive oxygen metabolites. Dig Dis Sci 33:6S–15S, 1988
Grisham MB: Oxidants and free radicals in inflammatory bowel disease. Lancet 344:859–861, 1994
Green AR: Peptide regulatory factors: Multifunctional mediators of cellular growth and differentiation. Lancet 1:705–707, 1989
Sporn MB, Roberts AB: Autocrine secretion—10 years later. Ann Intern Med 117:408–414, 1992
Nathan C, Sporn M. Cytokines in context: J Cell Biol 113:981–986, 1991
Sporn MB, Roberts AB: Transforming growth factor-[beta]: Recent progress and new challenges. J Cell Biol 119:1017–1021, 1992
Dignass AU, Sturm A: Peptide growth factors in the intestine. Eur J Gastroenterol Hepatol 13(7):763–770, 2001
Wong WM, Wright NA: Epidermal growth factor, epidermal growth factor receptors, intestinal growth, and adaptation. J Parenter Enteral Nutr 23:S83–S88, 1999
Challacombe DN, Wheeler EE: Trophic action of epidermal growth factor on human duodenal mucosa cultured in vitro. Gut 32:991–993, 1991
Reeves JR, Richards RC, Cooke T: The effects of intracolonic EGF on mucosal growth and experimental carcinogenesis. Br J Cancer 63:223–226, 1991
Kurokowa M, Lynch K, Podolsky DK: Effects of growth factors on an intestinal epithelial cell line: Transforming growth factor beta inhibits proliferation and stimulates differentation. Biochem Biophys Res Commun 142:775–782, 1987
Carpenter G, Cohen S. Epidermal growth factor: J Biol Chem 265:7709–7712, 1990
Fitzpatrick LR, Wang P, Johnson LR: Effect of epidermal growth on polyamine-synthesizing enzymes in rat enterocytes. Am J Physiol 252:G209–G214, 1987
Opleta-Madsen K, Hardin J, Gall DG: Epidermal growth factor upregulates intestinal electrolyte and nutrient transport. Am J Physiol 260:G807–G814, 1991
Riegler M, Sedivy R, Sogukoglu T, et al.: Epidermal growth factor promotes rapid response to epithelial injury in rabbit duodenum in vitro. Gastroenterology 111:28–36, 1996
Dignass AU, Podolsky DK: Cytokine modulation of intestinal epithelial cell restitution: Central role of transforming growth factor beta. Gastroenterology 105:1323–1332, 1993
Sullivan PB, Brueton MJ, Tabara ZB, Goodlad RA, Lee CY, Wright NA: Epidermal growth factor in necrotising enteritis. Lancet 338:53–54, 1991
Chowdhury A, Fukuda R, Fukumoto S: Growth factor mRNA expression in normal colorectal mucosa and in uninvolved mucosa from ulcerative colitis patients. J Gastroenterol 31:353–360, 1996
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Jahanshahi, G., Motavasel, V., Rezaie, A. et al. Alterations in Antioxidant Power and Levels of Epidermal Growth Factor and Nitric Oxide in Saliva of Patients with Inflammatory Bowel Diseases. Dig Dis Sci 49, 1752–1757 (2004). https://doi.org/10.1007/s10620-004-9564-5
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10620-004-9564-5